Shark cartilage

This article was originally published in The Tan Sheet

21 Sep 1998
News

The Tan Sheet

Executive Summary

Saint Foy, Quebec-based AEterna Labs selected by the National Cancer Institute to conduct Phase III trials of the biotech lab's angiogenesis inhibitor AE-941/Neovastat, a liquid shark cartilage extract. The trials will attempt to evaluate the agent in the treatment of cancer, and will be conducted in hospitals throughout the U.S. and Canada beginning in early 1999. The studies are to include a double-blind, placebo-controlled trial administered to several hundred cancer patients

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Industries
Consumer
Subjects
OTC Drugs

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

Consumer OTC Drugs

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS088878

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS088878

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Shark cartilage

News

Executive Summary

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert